(Q36069858)

12 August 2017

Serum sclerostin and risk of hip fracture in older Caucasian women (English)

1 reference

12 August 2017

1 reference

Jane A Cauley

6

0 references

Kristine Ensrud

7

object named as

Kristine E Ensrud

1 reference

Study of Osteoporotic Fractures Research Group

12 August 2017

9

object named as

Study of Osteoporotic Fractures Research Group

1 reference

12 August 2017

2

Peggy M Cawthon

1 reference

12 August 2017

8

Steven R Cummings

1 reference

12 August 2017

Aarthi Arasu

1

1 reference

12 August 2017

Li-Yung Lui

3

1 reference

12 August 2017

Thy P Do

4

1 reference

12 August 2017

Puneet S Arora

5

1 reference

12 August 2017

language of work or name

English

0 references

publication date

30 March 2012

1 reference

The Journal of Clinical Endocrinology and Metabolism

12 August 2017

1 reference

12 August 2017

97

1 reference

12 August 2017

6

1 reference

12 August 2017

2027-2032

1 reference

Relation of age, gender, and bone mass to circulating sclerostin levels in women and men.

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387417

Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387417

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387417

Regulation of circulating sclerostin levels by sex steroids in women and in men.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387417

Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387417

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387417

Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387417

SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387417

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387417

Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387417

Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387417

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387417

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387417

Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387417

Nonresponders to osteoporosis therapy

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387417

The natural history of sclerosteosis

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387417

Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss

23 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22466341

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22466341

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

An estimate of the worldwide prevalence, mortality and disability associated with hip fracture

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22466341

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1210/JC.2011-3419

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

22466341

1 reference